SCHEMBL4128846

SCHEMBL4128846

CCCOc1cc2c(OCCC)cccc2cc1/C=C1/SC(Nc2ccc(CC(=O)O)cc2)=NC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPC1 O15118 2/20 0.40
TDP1 Q9NUW8 2/20 0.36
POLB P06746 3/20 0.35
MAPT P10636 4/20 0.35
TP53 P04637 3/20 0.35
PDE4B Q07343 3/20 0.35
PDE4D Q08499 3/20 0.35
HPGD P15428 1/20 0.35
CISD1 Q9NZ45 1/20 0.34
IKBKB O14920 1/20 0.34
MDM2 Q00987 2/20 0.33
KDM4E B2RXH2 2/20 0.33
RECQL P46063 2/20 0.33
AGPAT2 O15120 2/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.33
PDGFRB P09619 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128848 1.00 MEN1 (0.43) MEN1KMT2ANPC1TDP1POLB
SCHEMBL4127754 0.91 KMT2A (0.46) MEN1KMT2ANPC1TDP1POLB
SCHEMBL4127749 0.91 KMT2A (0.46) MEN1KMT2ANPC1TDP1POLB
SCHEMBL4635225 0.87 KMT2A (0.40) MEN1KMT2ANPC1TDP1POLB
SCHEMBL4131927 0.87 KMT2A (0.42) MEN1KMT2ANPC1TDP1POLB
SCHEMBL4131931 0.87 KMT2A (0.42) MEN1KMT2ANPC1TDP1POLB
SCHEMBL4635223 0.86 MEN1 (0.39) MEN1KMT2ANPC1TDP1POLB
SCHEMBL4122284 0.85 PDE4B (0.42) TDP1MAPTTP53PDE4BPDE4D
SCHEMBL4122280 0.85 PDE4B (0.42) TDP1MAPTTP53PDE4BPDE4D
Acetic Acid SCHEMBL4133643 0.82 TDP1 (0.36) MEN1KMT2ANPC1TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ MEN1 4075/4885KMT2A 2895/4885NPC1 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.